Center for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.
Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.
Blood. 2022 Nov 3;140(18):1993-1997. doi: 10.1182/blood.2022018052.
Two Letters to address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.
两封致信，探讨血液系统疾病前体人群 COVID-19 风险。在第一篇文章中，Miller 及其同事报告了中等潜在克隆性造血（CHIP）是否与 COVID-19 的不良结局相关，发现 CHIP 与 28 天死亡率之间无关联，同时提供了间接关联 IL-6 信号和患者结局的数据。在第二篇文章中，Ho 及其同事研究了 COVID-19 合并意义未明的单克隆丙种球蛋白血症（MGUS）患者的结局，报告称四分之一患者发生严重感染，多变量分析显示，如果存在免疫缺陷，则更有可能出现不良结局。
